7 Market Access Trends Reshaping Pharma by 2027
The rules of pharmaceutical market access are being rewritten. From IRA-mandated price ceilings to AI-driven outcomes contracting.
Athithi
Pfizer and Innovent Strike $10.5B Oncology Collaboration
Pfizer has signed one of the year’s largest cross-Pacific oncology deals, pledging $650 million upfront and up to $9.85 billion in milestones to co-develop 12 early-stage cancer assets with China’s Innovent Biologics.
The ADC Decade Accelerates: What to Watch at ASCO 2026
The antibody–drug conjugate field arrives at ASCO 2026 in a fundamentally different shape. This Synopulse pre-conference briefing maps the five catalysts, 16+ assets, and strategic themes that will reshape the competitive landscape.
NHS Gives Green Light to Life-Changing SMA Treatments
NICE has recommended routine NHS access to nusinersen and risdiplam for spinal muscular atrophy.
NICE backs digital asthma tools for NHS use as evidence builds
The UK health watchdog National Institute for Health and Care Excellence (NICE) has recommended a suite of digital platforms to help people with asthma better manage their condition, signalling growing confidence in app-based tools as part of routine care, while stopping short of full endorsement pending further evidence. In draft guidance published yesterday, NICE said … Read more
IQWiG Highlights Evidence Gaps Despite Growing Treatment Options
Last week’s policy signals from Germany underscored a clear regulatory theme: access increasingly hinges on comparative evidence, not just innovation or unmet need. New assessments from the Institute for Quality and Efficiency in Health Care (IQWiG) highlighted where evidence is strong enough to support added benefit, where gaps remain despite growing treatment options. Multiple myeloma: … Read more
CMS Confirms 2026 Coverage for MTF’s AmnioBand, AlloPatch
CMS confirms Medicare coverage for MTF Biologics’ AmnioBand Membrane and AlloPatch Pliable under updated LCDs for diabetic foot and venous leg ulcers starting 2026.
BioStem Lands 2026 CMS Status Quo Coverage for Skin Grafts
CMS places BioStem’s VENDAJE products in a 12-month status quo category, preserving DFU and VLU reimbursement through 2026 while evidence review continues.
ENvue’s UroShield Secures UK NHS Reimbursement
ENvue Medical’s UroShield Kit is added to the NHS Drug Tariff Part IX, enabling nationwide reimbursement and triggering early commercial orders in the UK.
Dren Bio, Sanofi Expand $1.8B B-Cell Depletion Alliance
Dren Bio has expanded its strategic collaboration with Sanofi in a deal worth up to $1.8 billion, advancing next-generation B-cell depletion therapies and reinforcing deep-remission strategies in autoimmune disease.